VESTAL, N.Y. — Binghamton University researchers will use two federal grants totaling more than $1.3 million for research into antibody-mediated, drug-delivery technology for the treatment of cancer and autoimmune disorders.
L. Nathan Tumey — assistant professor of pharmaceutical sciences at Binghamton University — is the principal investigator on both grants, per a university news release. The funding includes $1.2 million from the National Institute of General Medical Sciences and $150,000 from the National Institute of Allergy and Infectious Diseases.
Tracy Brooks, associate professor of pharmaceutical sciences, and Fake (Frank) Lu, assistant professor of biomedical engineering, will collaborate with Tumey on the four-year, $1.2 million grant titled “Exploiting the Hydrophobic Glycosyl Pocket of IgGI for Imaging and Drug Delivery Applications.”
(Sponsored)
New Sexual Harassment Policy and Training Requirements. Does Your Policy Comply?
New York State requires all employers to provide annual sexual harassment prevention training and a harassment policy to its employees. This requirement applies to all employees, including hourly and salaried,
The Influence of Economic Uncertainty on Business Value
Businesses face uncertain conditions today, including geopolitical and cybersecurity risks, inflation concerns, environmental issues, and a lack of clarity about future tax laws and interest rates. Here’s an overview of
About the research
Both grants are focused on antibody-drug-conjugate (ADC) technology in which the specificity of an antibody is used to deliver a drug to specific tissue types.
“One of major challenges in the development of ADCs is how and where to attach the drug to the antibody,” Tumey said. “Traditionally, we have randomly attached the drug to various residues on the antibody. However, over the years we’ve figured out that the site of attachment is very important to the safety and efficacy of the ADC.”
Tumey and his collaborators have found a way to attach drugs to a “privileged region” of the antibody.
“We have discovered a new method for attaching drugs to one very specific residue, Glutamine 295,” he said.
The advantages it brings are two-fold.
“One is that we are attaching at a location on the antibody (a shielded hydrophobic pocket) that naturally protects the drug from metabolic enzymes. The other unique aspect of this technology we’ve invented is that it does not require antibody engineering — thus allowing anyone to attach drugs to their antibody of interest without having to make changes to the antibody backbone,” he explained.
Tumey stressed that the trio is developing a technology, not a drug.
“We’re trying to show that this technology is useful for delivering drugs. Our hope is to demonstrate that this methodology is equivalent or better than existing conjugation technology — and to eventually use it for the preparation of therapeutic agents,” he said.
The second grant
Tumey is the sole investigator on the two-year, $150,000 grant, entitled “Molecular whack-a-mole”: Targeting Transmembrane-TNFα for the Delivery of Anti-Inflammatory Drugs.”
“This project is about developing therapeutic ADCs that deliver immunosuppressive payloads using antibodies against a particular protein (TNFα) that is found only on inflamed cells,” he said. “Can we deliver an immune-suppressing agent specifically to the cells expressing this protein in order to calm things down?
“Ultimately, we are designing ADCs that could be employed in the treatment of autoimmune disorders like Rheumatoid Arthritis, Lupus and Crohn’s disease, each of which are driven (at least in part) by over-production of TNFα. By delivering the drug specifically to the TNFα-expressing cells, we hope to be able to ameliorate the inflammation without the side effects that are associated with traditional immunosuppressive agents.” Tumey explained.
